May 28, 2014
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
NovaBay completes enrollment for international viral conjunctivitis trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NovaBay Pharmaceuticals Inc. announced it has completed patient enrollment in its global phase 2b trial, BAYnovation, testing its solution to treat adenoviral conjunctivitis.
The multicenter, randomized clinical study has enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil, according to the press release.
“BAYnovation was designed to evaluate the efficacy of NovaBay's auriclosene ophthalmic solution in the treatment of adenoviral infection, specifically clearing the associated red eye and reducing lingering effects left by the infection,” the press release explained.
David Stroman, PhD, senior vice president of ophthalmology at NovaBay, said they hope to report trial results in mid-2014.